DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
What is the purpose of this trial?
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Participation Guidelines
Ages: 18 years and younger
Gender: Both
Southwest Oncology Group (SWOG)
Start Date: 11/20/2017
End Date: 08/31/2020
Last Updated: 02/22/2018
Study HIC#: 2000020739
